A Randomized Prospective Clinical Trial Comparing Single Tooth Implant 3 Loading Protocols
NCT ID: NCT00607022
Last Updated: 2018-07-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
41 participants
INTERVENTIONAL
2007-12-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Immediately Placed Dental Implants With Local Application of Injectable PRF in Periodontally Compromised Sites
NCT04029779
Osseodensification and Dental Implant Stability
NCT05376020
Immediate Loading in Single Tooth Implants
NCT05409287
Immediate Versus Conventional Loading of Early Placed Dental Implant Supporting Single Crowns
NCT06693297
Implant Phenotype Modification Via GBR and ADM
NCT07082244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SEQUENCE OF VISITS A. Visit 1: Screening Examination
Subjects shall be seen for evaluation and for collection of baseline data. Pre-treatment data shall be recorded on case report forms. The visit shall include:
1. Explanation to the patient of the purposes of the study and the planned procedures related to the study.
2. Explanation to the subject of the risks and possible complications of participation in the study. Patients shall be notified that inclusion in the study is for the purpose of providing implant treatment only and that no provision for other active treatments are guaranteed or implied except for care related to the implant aspect of their oral cavity. This treatment shall be agreed upon as outlined for their specific case.
Implant Site Selection: Adequate bone volume is needed to accommodate the planned endosseous dental implant. This will mean sufficient height such that the implant would not encroach on vital structures (such as inferior alveolar nerve), and sufficient width that the implant could be placed within the confines of the existing bone without dehiscence or fenestration, requiring significant grafting at time of implant placement. Typically, this will mean space dimensions will be: 6 mm or greater ridge width facial-lingual and \> 6 mm in the mesial to distal dimension . If the implant can be placed and only a few screw threads are exposed, grafting is allowed to cover these threads. In the planned occlusal-gingival dimension, there must be at least 7 mm of space from the planned head of the implant to the planned occlusal plane.
The subject should be notified that inclusion in the study is conditional upon satisfying the inclusion and exclusion criteria as seen in Table 1. Only subjects satisfying the Inclusion/Exclusion criteria shall be enrolled.
The dental implant system to be used is the Astra Tech OsseoSpeed Dental Implant System (Astra Tech AB, Mölndal Sweden). This is an FDA cleared product under FDA 510k clearance act (FDA clearance 4/30/2004). This protocol calls for use of only the 4.0 mm diameter by 11 mm long dental implant (OsseoSpeed Aqua platform; Ref Number 24622; Astra Tech AB) in the anterior (incisor/canine) or posterior pre-molar regions of the mandible or maxilla. All sites must have sound natural or restored teeth/implants Mesial and Distal to the planned site of interest (Bounded Edentulous Space or BES). The patient should otherwise have a restored stable occlusion that is mutually protected. No implants will be placed in molar sites. The implant lengths accepted in the study are 11 mm. Clinical and radiographic screening will be used to limit the study to patients with sufficient bone quantity to completely encase the implant.
Upon review of the subject's health history, inclusion/exclusion criteria a screening clinical assessment will be made. Existing dental radiographs within the past 6 months shall be acceptable. No new radiographs will be made until subject enrollment and obtaining signed informed consent. The subject will be given an informed consent for the study and reviewed with the clinical study coordinator. Preliminary diagnostic impressions will made (Penta, 3M ESPE) and poured in dental stone (Whip Mix Corp., Louisville, KY). Implant subjects may have a pre-operative Cone Bean CT imaging study (Galileos; Sirona, Charlotte NC; www.sirona.com) made at the College of Dentistry's Department of Oral Maxillofacial Radiology at the discretion of the Principal Investigator following diagnostic work-up. Subjects shall be either patients of record of the College of Dentistry or shall be enrolled if new to the College. Patient records are electronic (WinDent) along with a paper version. Paper-based Case Report Forms (CRF) containing subject's medical information will be kept in one central file in a locked cabinet in the Dental Clinical Research Center. This data will be kept in a secured file accessible only by the PI and the Clinical Coordinator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
immediate load
immediate load of dental implant based on the bone quality determined by the insertion torque value
dental implant
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Loading at 6 weeks
delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
dental implant
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Loading at 12 weeks
traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
dental implant
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dental implant
Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand and sign the informed consent prior to starting the study.
* Ability and willingness to comply with all study requirements.
* Adequate oral hygiene (defined as an average Modified Sulcus Bleeding Index of 1 or less and an average Modified Plaque Index of 1 or less).
* Must be a bounded edentulous space.
* Adequate bone volume to accommodate the planned endosseous dental implant (e.g. sufficient height such that the implant would not encroach on vital structures such as inferior alveolar nerve, and sufficient width that the implant could be placed within the confines of the existing bone without dehiscence or fenestration, requiring significant grafting at time of implant placement). The only implant utilized in this protocol will be a 4.0 mm diameter by 11 mm long implant (Fixture OsseoSpeed Astra Tech).
Typically, this will mean space dimensions will be: 6 mm or greater ridge width facial-lingual and \> 6 mm in the mesial to distal dimension . If the implant can be placed and only a few screw threads are exposed, grafting is allowed to cover these threads. In the planned occlusal-gingival dimension, there must be at least 7 mm of space from the planned head of the implant to the planned occlusal plane.
* Osteotome use will be allowed but there must be a minimum of 8mm of bone height from the alveolar crest to the floor of the sinus. Maximum sinus lift will be 4 mm.
* Existing teeth are healthy and adequately restored, and desired a fixed restoration on implants.
* Patient has a mutually protected occlusion.
* The patient, if of childbearing potential, had a negative pregnancy test within one week prior to surgery.
Exclusion Criteria
* History of alcoholism or drug abuse within the past 5 years. - Severe bruxing or clenching habits
* Untreated periodontitis
* Patients at undue risk for an outpatient surgical procedure
* Presence of residual roots at the implant site- Patients with history of site development (extensive bone augmentation) at the implant site in the past 4 months.
* Placement of implant in an extraction site that had been healing for less than 2 month.
* Presence of local inflammation or mucosal diseases such as lichen planus.
* Uncontrolled diabetes (defined as HA1c \> 7.0 percent).
* Current hematologic disorder or chronic use of coumarin (or similar) anti-coagulant therapies.
* History of leukocyte dysfunction and deficiencies
* Metabolic bone disorders
* History of renal failure
* History of liver disease
* Immunocompromised patients having HIV, RA, SLE or other collagen vascular disorders.
* Chronic corticosteroid use.
* Current chemotherapy
* History of use of IV-based bisphosphonates.
* History of radiation treatment to the head or neck
* Patients requiring grafting of bone or mucosal tissue at the time of implant placement which would require submersion of the implant during the healing period.
* Use of any investigational drug or device within the 30 day period immediately prior to implant surgery
* Patients requiring submersion of implants for esthetic reasons.
* Patient requiring ongoing dental treatment in the same quadrant or opposing quadrant during the initial 16 week healing period.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dentsply Sirona Implants and Consumables
INDUSTRY
Clark Stanford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clark Stanford
Associate Dean for Research & Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clark Stanford, DDS, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Iowa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Iowa College of Dentistry
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200710722
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.